Low-frequency KRAS mutations are prevalent in lung adenocarcinomas
A partir d'échantillons de tissu tumoral et de tissu sain prélevés sur des patients atteints d'un adénocarcinome du poumon, cette étude identifie des populations sous-clonales présentant des mutations du gène KRAS et susceptibles de contribuer à la résistance aux thérapies ciblées anti EGFR
Aim: This study quantified low-frequency KRAS mutations in normal lung and lung adenocarcinomas, to understand their potential significance in the development of acquired resistance to EGFR-targeted therapies. Materials & methods: Allele-specific Competitive Blocker-PCR was used to quantify KRAS codon 12 GAT (G12D) and GTT (G12V) mutation in 19 normal lung and 21 lung adenocarcinoma samples. Results: Lung adenocarcinomas had KRAS codon 12 GAT and GTT geometric mean mutant fractions of 1.94 × 10-4 and 1.16 × 10-3, respectively. For 76.2% of lung adenocarcinomas, the level of KRAS mutation was greater than the upper 95% confidence interval of that in normal lung. Conclusion: KRAS mutant tumor subpopulations, not detectable by DNA sequencing, may drive resistance to EGFR blockade in lung adenocarcinoma patients.